D.E. Shaw & Co
STRO icon

D.E. Shaw & Co’s Sutro Biopharma STRO Stock Holding History

D.E. Shaw & Co’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
+30,128
New +$939K ﹤0.01% 3750
2025
Q2 		– Sell
-15,804
Closed -$103K – 4704
2025
Q1 		$103K Buy
15,804
+36
+0.2% +$567 ﹤0.01% 4013
2024
Q4 		$290K Sell
15,768
-997
-6% -$30.4K ﹤0.01% 3910
2024
Q3 		$580K Buy
16,765
+3,898
+30% +$153K ﹤0.01% 3612
2024
Q2 		$377K Sell
12,867
-11,297
-47% -$447K ﹤0.01% 3779
2024
Q1 		$1.37M Buy
+24,164
New +$1.07M ﹤0.01% 2895
2023
Q3 		– Sell
-4,072
Closed -$189K – 4485
2023
Q2 		$189K Sell
4,072
-11,448
-74% -$570K ﹤0.01% 3753
2023
Q1 		$717K Sell
15,520
-12,039
-44% -$764K ﹤0.01% 3372
2022
Q4 		$2.23M Sell
27,559
-3,942
-13% -$274K ﹤0.01% 2850
2022
Q3 		$1.75M Buy
31,501
+5,561
+21% +$329K ﹤0.01% 3118
2022
Q2 		$1.35M Buy
+25,940
New +$1.45M ﹤0.01% 3414
2022
Q1 		– Sell
-3,066
Closed -$456K – 5922
2021
Q4 		$456K Sell
3,066
-673
-18% -$121K ﹤0.01% 4454
2021
Q3 		$706K Buy
3,739
+841
+29% +$160K ﹤0.01% 3861
2021
Q2 		$539K Sell
2,898
-1,363
-32% -$267K ﹤0.01% 4003
2021
Q1 		$970K Sell
4,261
-5,602
-57% -$1.33M ﹤0.01% 3139
2020
Q4 		$2.14M Buy
+9,863
New +$1.63M ﹤0.01% 2512

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

D.E. Shaw & Co's STRO Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Sutro Biopharma (STRO) in Q2 2026: 30,128 shares worth $1M. The stake represents ﹤0.01% of the portfolio and ranks #3750 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in STRO as recently as Q1 2025.

D.E. Shaw & Co first reported a position in STRO in Q4 2020 and has held it in 16 quarters since. The position peaked at $2.23M in Q4 2022. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • D.E. Shaw & Co held 30,128 shares of Sutro Biopharma worth $1M as of Q2 2026.
  • Sutro Biopharma was a new D.E. Shaw & Co position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3750 holding.
  • D.E. Shaw & Co first reported a position in Sutro Biopharma in Q4 2020 and has held it in 16 quarters since.
  • D.E. Shaw & Co's Sutro Biopharma position peaked at $2.23M in Q4 2022.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.